Overview

Detailed Summary

Bal Pharma Ltd (BPL) is part of the Mcro Laboratories Group, specializing in the manufacture and marketing of pharmaceutical formulations like paracetamol, gliclazide, etc.
The company has progressively expanded its product range and entered cardiac specialities, utilizing divisions like 'SERVETUS' for dedicated marketing.
BPL has recently launched new drug formulations like Sitagliptin and its combination with Metformin, indicating product innovation.
Historically, BPL has engaged in strategic acquisitions, such as Golden Drugs Pvt Ltd, enhancing its manufacturing capabilities and portfolio diversification.
The company's ongoing investment in an integrated API unit reflects its commitment to expanding production capacity and operational scope.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 125 Cr
Volatility: Low Risk
P/E Ratio: 14.8
Industry P/E: 32.2
PEG Ratio: —
P/B Ratio: 1.6
52W High: 119.60
52W Low: 59.69

Sales CAGR

1Y: -10.65%
3Y: 2.56%
5Y: 12.13%
10Y: 4.60%

Profit CAGR

1Y: -2.82%
3Y: -3.12%
5Y: —
10Y: 12.03%

ROE

TTM: 8.71%
3Y: 8.06%
5Y: 8.47%
10Y: 4.14%

ROCE

TTM: 8.78%
3Y: 18.54%
5Y: 18.90%
10Y: 14.32%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
GUJINJEC		89.95	132 Cr	499.72	12.96	0.00	4.19	5.58	2.14
KREBSBIO		45.60	131 Cr	-4.30	0.00	0.00	14.21	-14.91	-13.78
ACHYUT		5.50	130 Cr	275.00	4.12	0.00	1.74	2.24	0.00
SOTAC		102.65	129 Cr	24.38	2.43	0.00	15.37	16.39	8.19
GODAVARI		92.00	127 Cr	18.74	1.91	0.00	12.65	11.11	2.27
BALPHARMA		75.31	124 Cr	14.77	1.59	1.54	8.71	8.78	2.33
LACTOSE		86.40	123 Cr	23.10	1.97	0.00	7.24	10.49	3.50
Median: 7 Co.	—	86.40	129 Cr	23.10	1.97	0.00	8.71	8.78	2.27

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	93	82	95	74	74	73	82	66	74	88
Expenses	85	74	85	68	66	65	74	60	68	78
Operating Profit	7.70	7.79	9.60	6.47	7.69	7.76	7.64	6.06	5.72	9.55
OPM %	8.32	9.54	10.14	8.70	10.44	10.61	9.33	9.20	7.73	10.89
Other Income	0.14	0.10	2.45	0.82	-0.20	0.51	1.08	0.72	1.12	0.33
Interest	3.82	3.66	4.14	4.24	3.65	5.01	3.95	4.05	3.86	4.85
Depreciation	2.42	2.96	2.16	2.43	2.48	2.69	2.18	2.52	2.27	3.23
Profit Before Tax	1.60	1.27	5.75	0.62	1.36	0.57	2.59	0.21	0.72	1.79
Tax %	39.38	33.07	3.83	58.06	23.53	8.77	-109.27	0.00	0.00	0.00
Net Profit	0.97	0.85	5.53	0.26	1.04	0.52	5.42	0.21	0.72	1.79
EPS in Rs	0.61	0.54	3.71	0.16	0.65	0.33	3.40	0.13	0.45	1.12

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	235	211	225	171	251	281	304	339	303	295
Expenses	214	194	208	166	226	258	279	308	274	265
Operating Profit	21	17	18	4.88	24	23	25	32	30	29
OPM %	8.88	8.07	7.78	2.85	9.76	8.35	8.26	9.29	9.75	9.90
Other Income	3.04	1.73	1.01	1.85	1.14	5.15	0.94	2.85	2.20	2.11
Interest	8.49	9.14	13	13	12	10	12	15	17	17
Depreciation	6.49	6.77	6.15	7.68	9.52	9.04	9.13	10	9.77	9.87
Profit Before Tax	2.87	2.88	-0.20	-14	4.10	9.18	4.75	9.05	5.14	4.73
Tax %	113.79	86.94	1,163.74	4.71	-14.86	37.87	44.84	17.70	-40.86	-52.01
Net Profit	-0.40	0.38	2.15	-13	4.71	5.70	2.62	7.45	7.24	7.19
EPS in Rs	-0.62	—	2.21	-7.80	3.08	3.43	1.65	4.92	4.54	5.10
Dividend Payout %	80.65	50.94	37.45	0.00	29.94	26.39	59.52	24.19	26.43	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	13	14	14	14	14	15	15	16	16	16
Reserves	42	48	51	52	38	39	44	48	53	61
Borrowings	85	89	103	116	113	105	98	131	140	150
Other Liabilities	71	82	92	79	73	82	104	118	111	108
Total Liabilities	211	233	260	261	238	240	261	313	320	336
Fixed Assets	56	60	71	70	71	69	67	76	77	87
CWIP	3.93	1.70	0.21	3.63	3.32	0.00	1.61	0.00	0.47	2.79
Investments	0.02	0.02	0.02	0.02	0.00	0.00	0.00	0.00	6.76	2.47
Other Assets	151	172	188	187	164	171	192	237	235	244
Total Assets	211	233	260	261	238	240	261	313	320	336

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-19	6.31	0.58	7.76	23	22	27	-1.54	23	20
Cash from Investing Activity	-14	-7.96	-3.56	-8.04	-4.71	-5.53	-9.48	-22	-19	-15
Cash from Financing Activity	32	-5.94	3.53	0.01	-20	-17	-17	24	-1.21	-7.84
Net Cash Flow	-0.86	-7.58	0.55	-0.27	-1.43	0.17	0.09	0.37	2.71	-2.44

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	51.61%	51.61%	51.23%	51.23%	51.23%	50.86%	50.86%	50.86%	50.86%	50.86%	50.86%	50.86%
FIIs	0.17%	0.14%	0.13%	0.13%	0.13%	0.13%	0.14%	0.14%	0.15%	0.22%	0.14%	0.14%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.00%	0.00%	0.00%	0.00%
Public	48.23%	48.25%	48.64%	48.64%	48.64%	49.01%	49.00%	49.00%	48.99%	48.92%	49.01%	49.01%
Total Shareholders	15,869	15,529	15,060	14,772	15,014	16,007	15,667	15,723	15,826	15,774	15,520	15,214

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY23

Investor Presentation

Q3 FY23

Investor Presentation

Q1 FY23

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q1 FY23

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Bal Pharma Ltd

Bal Pharma Ltd (BALPHARMA) is currently trading at 78.49 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bal Pharma Ltd (BPL) is part of the Mcro Laboratories Group, specializing in the manufacture and marketing of pharmaceutical formulations like paracetamol, gliclazide, etc. The company has progressively expanded its product range and entered cardiac specialities, utilizing divisions like 'SERVETUS' for dedicated marketing. BPL has recently launched new drug formulations like Sitagliptin and its combination with Metformin, indicating product innovation. Historically, BPL has engaged in strategic acquisitions, such as Golden Drugs Pvt Ltd, enhancing its manufacturing capabilities and portfolio diversification. The company's ongoing investment in an integrated API unit reflects its commitment to expanding production capacity and operational scope.

Over the past 52 weeks, Bal Pharma Ltd has traded between a low of ₹59.69 and a high of ₹119.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bal Pharma Ltd has a market capitalization of approximately 124.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bal Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 14.77 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 124.93 Cr, Bal Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bal Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bal Pharma Ltd is 14.77. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Bal Pharma Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison